Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Article ID	Journal	Published Year	Pages	File Type
6073977	Journal of the American Academy of Dermatology	2012	11 Pages	PDF

Abstract

Adalimumab efficacy was well maintained over more than 3 years of continuous therapy for patients with sustained initial PASI 75 responses. Maintenance was best at the PASI 100 level.

Keywords

PASI 100 OLE Adalimumab PASI 90 LOCF every other week Open-label extension PASI 75 Efficacy eow Safety PASI Long-term treatment Adverse events Open-label last observation carried forward psoriasis area and severity index Psoriasis Clinical trial